Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, will participate in a panel discussion at Fierce Biotech Week in Boston, MA from October 7-9, 2025. The company's Senior Vice President of Research and Development, Dr. Marie O'Farrell, will join a panel focused on AI/Machine Learning applications in biotechnology.
The presentation, scheduled for October 9, 2025, at 11:15 AM ET, will highlight Sagimet's use of AI-based digital pathology platforms in clinical trials, particularly for analyzing liver biopsies in metabolic dysfunction associated steatohepatitis (MASH) drug development.
Sagimet Biosciences (Nasdaq: SGMT), una società biofarmaceutica in fase clinica, parteciperà a una tavola rotonda durante Fierce Biotech Week a Boston, MA, dal 7 al 9 ottobre 2025. Il Senior Vice President di Ricerca e Sviluppo della società, la Dott.ssa Marie O'Farrell, parteciperà a un panel dedicato alle applicazioni di AI/ML nella biotecnologia.
La presentazione, prevista per il 9 ottobre 2025 alle 11:15 AM ET, evidenzierà l'uso da parte di Sagimet di piattaforme di patologia digitale basate sull'IA nei trial clinici, con particolare riguardo all'analisi di biopsie epatiche nello sviluppo di farmaci per la steatoepatite metabolica associata a disfunzione metabolica (MASH).
Sagimet Biosciences (Nasdaq: SGMT), una empresa biofarmacéutica en fase clínica, participará en una mesa redonda durante Fierce Biotech Week en Boston, MA, del 7 al 9 de octubre de 2025. La vicepresidenta senior de Investigación y Desarrollo de la empresa, la Dra. Marie O'Farrell, se unirá a un panel centrado en las aplicaciones de IA/ML en biotecnología.
La presentación, programada para el 9 de octubre de 2025 a las 11:15 AM ET, destacará el uso de Sagimet de plataformas de patología digital basadas en IA en ensayos clínicos, especialmente para analizar biopsias hepáticas en el desarrollo de fármacos para la esteatohepatitis metabólica asociada a disfunción metabólica (MASH).
사기멧 바이오사이언스(Sagimet Biosciences)(나스닥: SGMT), 임상 단계 생물의약기업은 2025년 10월 7일부터 9일까지 매사추세츠주 보스턴에서 열리는 Fierce Biotech Week의 패널 토론에 참여합니다. 연구개발 수석 부사장인 Dr. Marie O'Farrell이 생명공학에서의 AI/머신러닝 응용에 관한 패널에 합류합니다.
발표는 2025년 10월 9일 동부 표준시 11:15에 예정되어 있으며, 임상시험에서의 AI 기반 디지털 병리 플랫폼 활용과 특히 대사 기능 장애 관련 지방간염(MASH) 약물 개발에서의 간 생검 분석을 강조합니다.
Sagimet Biosciences (Nasdaq: SGMT), une société biopharmaceutique en phase clinique, participera à une table ronde lors de Fierce Biotech Week à Boston, MA, du 7 au 9 octobre 2025. La vice-présidente senior Recherche et Développement de l'entreprise, le Dr Marie O'Farrell, se joindra à un panel axé sur les applications de l'IA/apprentissage automatique en biotechnologie.
La présentation, prévue le 9 octobre 2025 à 11h15 HE, mettra en lumière l'utilisation par Sagimet de plateformes de pathologie numérique basées sur l'IA dans les essais cliniques, en particulier pour l'analyse de biopsies hépatiques dans le développement de médicaments pour la stéato-hépatose métabolique associée à une dysfonction métabolique (MASH).
Sagimet Biosciences (Nasdaq: SGMT), ein klinisch-phasenweises Biopharmaunternehmen, wird an einer Podiumsdiskussion während der Fierce Biotech Week in Boston, MA, vom 7. bis 9. Oktober 2025 teilnehmen. Der Senior Vice President für Forschung und Entwicklung des Unternehmens, Dr. Marie O'Farrell, wird einem Panel beitreten, das sich auf KI/ML-Anwendungen in der Biotechnologie konzentriert.
Die Präsentation, geplant für den 9. Oktober 2025 um 11:15 Uhr ET, wird Sagiments Einsatz KI-basierter digitaler Pathologie-Plattformen in klinischen Studien hervorheben, insbesondere für die Analyse von Leberbiopsien in der Entwicklung von Medikamenten gegen metabolisch bedingte Steatohepatitis (MASH).
Sagimet Biosciences (ناسداك: SGMT)، هي شركة أدوية حيوية في مرحلة التجارب السريرية، ستشارك في جلسة نقاش ضمن أسبوع Fierce Biotech في بوسطن، ماساتشوستس من 7 إلى 9 أكتوبر 2025. ستنضم نائبة رئيس البحث والتطوير في الشركة، الدكتورة ماري أوفاريل، إلى لجنة تركّز على تطبيقات الذكاء الاصطناعي/التعلم الآلي في التكنولوجيا الحيوية.
العرض المقرر في 9 أكتوبر 2025 الساعة 11:15 صباحاً بتوقيت شرق الولايات المتحدة، سيوضح استخدام Sagimet لمنصات علم الأمراض الرقمية القائمة على الذكاء الاصطناعي في التجارب السريرية، خاصةً لتحليل الخزعات الكبدية في تطوير أدوية لالتهاب الكبد الدهني المرتبط بالاختلالات الأيضية (MASH).
Sagimet Biosciences（纳斯达克：SGMT），一家处于临床阶段的生物制药公司，将于2025年10月7日至9日在马萨诸塞州波士顿举行的 Fierce Biotech Week 参与小组讨论。该公司研发高级副总裁 Marie O'Farrell 博士将加入一个聚焦生物技术中人工智能/机器学习应用的讨论小组。
该演讲定于2025年10月9日美国东部时间11:15，演讲将展示Sagimet在临床试验中使用的基于人工智能的数字病理学平台，特别是在代谢功能障碍相关脂肪肝炎（MASH）药物开发中的肝活检分析。
- None.
- None.
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced its participation in a drug development panel at Fierce Biotech Week taking place October 7-9, 2025 in Boston, MA.
| Panel Title: | How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROI |
| Presenter: | Marie O’Farrell, Ph.D., Senior Vice President of Research and Development, Sagimet Biosciences |
| Date and time: | Thursday, October 9, 2025, 11.15am ET |
| Panel Overview: | Discussion of the use of AI in the drug development space. Sagimet plans to share how it is employing state-of-the-art AI-based digital pathology platforms to complement conventional biopsy approaches in clinical trials. For drug development in metabolic dysfunction associated steatohepatitis (MASH), AI can enable granular objective quantitation of histology and enhance the ability to analyze morphology and spatial configuration of steatosis and fibrosis in liver biopsies. |
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When is Sagimet Biosciences (SGMT) presenting at Fierce Biotech Week 2025?
Who will represent Sagimet Biosciences (SGMT) at the Fierce Biotech Week panel?
What will Sagimet Biosciences (SGMT) discuss at the Fierce Biotech Week panel?
Where is the Fierce Biotech Week 2025 conference being held?
